Published in PLoS One on July 09, 2013
Estrogen receptor α enhances the transcriptional activity of ETS-1 and promotes the proliferation, migration and invasion of neuroblastoma cell in a ligand dependent manner. BMC Cancer (2015) 0.86
MicroRNA expression profiles differentiate chronic pain condition subtypes. Transl Res (2015) 0.77
The complex nature of oestrogen signalling in breast cancer: enemy or ally? Biosci Rep (2016) 0.76
The Estrogen Receptor α-Cistrome Beyond Breast Cancer. Mol Endocrinol (2016) 0.76
ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The Ki-67 protein: from the known and the unknown. J Cell Physiol (2000) 16.48
A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods (1994) 5.34
Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat (2004) 4.89
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
ETS transcription factors and their emerging roles in human cancer. Eur J Cancer (2005) 3.55
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 3.33
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol (2003) 3.04
The biology of the Ets1 proto-oncogene. Mol Cancer (2003) 2.88
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res (2005) 2.46
Ets proteins in biological control and cancer. J Cell Biochem (2004) 2.24
miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res (2011) 2.22
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One (2011) 2.16
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
A novel modulator domain of Ets transcription factors. Genes Dev (1992) 1.97
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol (2004) 1.89
The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer (2005) 1.76
MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids (1975) 1.72
Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther (2007) 1.65
Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst (1978) 1.55
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res (2005) 1.38
Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. EMBO J (1996) 1.36
Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem (2004) 1.35
Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene (2002) 1.34
c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol (1992) 1.33
Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro (1977) 1.31
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res (2012) 1.30
Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology (2008) 1.24
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res (2006) 1.23
Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett (1980) 1.21
Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem (2001) 1.20
Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors. Mol Cell Biol (2000) 1.13
ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene (2004) 1.11
Secondary structure of the ETS domain places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins. Biochemistry (1994) 1.10
A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res (1999) 1.10
Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat (2003) 1.08
Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. Br J Cancer (2002) 1.08
ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest (2012) 1.05
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.05
The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol (2004) 1.02
The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta. Mol Cancer Res (2012) 1.00
New insight into Ki67 expression at the invasive front in breast cancer. PLoS One (2013) 1.00
Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer (2001) 0.97
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int J Cancer (1996) 0.92
The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol (2003) 0.92
Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology (2011) 0.92
Regulation of hypoxia-inducible genes by ETS1 transcription factor. Carcinogenesis (2008) 0.89
Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T 47D). J Biol Chem (1981) 0.89
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer (2005) 0.88
Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. Breast Cancer Res Treat (2002) 0.82
Ras signaling and transcriptional synergy at a flexible Ets-1/Pit-1 composite DNA element is defined by the assembly of selective activation domains. J Biol Chem (2003) 0.81
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism. J Med Chem (2007) 0.80
Does a truncated form of the transcription factor Ets1 exist in breast cancer cells? Br J Cancer (2006) 0.78
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel) (2013) 1.65
The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol Cell Endocrinol (2003) 1.45
Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line. Genes Chromosomes Cancer (2013) 1.42
ETS transcription factors in endocrine systems. Trends Endocrinol Metab (2007) 1.33
Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res (2010) 1.26
Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther (2013) 1.13
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. Genes Chromosomes Cancer (2007) 1.06
Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Mol Cell Biol (2010) 1.03
Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer (2010) 1.02
Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosomes Cancer (2011) 1.01
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer (2012) 0.94
Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Res (2013) 0.90
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J Steroid Biochem Mol Biol (2010) 0.86
An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis (2010) 0.85
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation. J Vet Diagn Invest (2011) 0.85
HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. BMC Vet Res (2013) 0.85
Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia (2006) 0.83
Speed of human biological form and motion processing. PLoS One (2013) 0.82
A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter. Mol Endocrinol (2009) 0.82
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One (2011) 0.82
Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding. Proc Natl Acad Sci U S A (2002) 0.81
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol (2013) 0.81
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer (2011) 0.81
The 26-amino acid beta-motif of the Pit-1beta transcription factor is a dominant and independent repressor domain. Mol Endocrinol (2009) 0.79
Gene expression of vitamin D metabolic enzymes at baseline and in response to vitamin D treatment in thyroid cancer cell lines. Oncology (2012) 0.78
PRL-releasing peptide stimulation of PRL gene transcription--enter AKT. Endocrinology (2002) 0.77
RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer (2012) 0.76
Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res (2014) 0.75
Predictors of At-Home Arterial Oxygen Desaturation Events in Ambulatory Surgical Patients. J Patient Saf (2016) 0.75